{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:56:46Z","timestamp":1781636206849,"version":"3.54.5"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patient-reported outcomes (PROs) are key outcomes of importance for people with chronic kidney disease (CKD), and may be of even higher relevance for patients with concomitant anemia which can often be symptomatic. Thus, PROs should be included as outcomes in clinical trials of interventions delivered to people with CKD. We evaluated the reporting of PROs in randomized controlled trials (RCTs) of anemia treatments delivered to people with CKD, assessing adherence to Consolidated Standards of Reporting Trials (CONSORT)-PRO reporting guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>We conducted a scoping review in October 2024 using PubMed, Embase, and the Cochrane Central Register of Controlled Trials to identify RCTs of anemia treatments delivered to people with CKD, and subsequently identified publications of these RCTs which reported PROs data. We appraised adherence to seven elements outlined in CONSORT-PRO guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 280 publications of 248 eligible RCTs, 41 publications (15%) reported PROs data for iron treatments (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916), erythropoiesis stimulating agents (ESAs;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922), hypoxia-inducible factor\u2013prolyl hydroxylase inhibitors (HIF-PHIs;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), or HIF-PHIs versus ESAs (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). Data were reported for 22 different PRO measures. Most publications did not adhere to CONSORT-PRO guidelines, with 39% identifying the PRO measure in the study abstract, 7% providing a hypothesis surrounding the PROs, 10% reporting methods of PRO data collection, 27% providing statistical methods for handling missing data, and 10% discussing PRO-specific limitations and implications for generalizability. No publication followed all seven CONSORT-PRO elements evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There are a limited number of publications reporting PROs from RCTs of anemia treatments delivered to people with CKD. PRO measures used, as well as methods of data reporting and analysis, are highly variable. These findings highlight the need to adhere to established guidelines for reporting PROs data, which will enable interpretability and reliability of data in caring for people with CKD and anemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01007-2","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T14:34:40Z","timestamp":1771684480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reporting of patient-reported outcomes (PROs) in randomized controlled trials of anemia treatments for people with CKD: a scoping review"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-839X","authenticated-orcid":false,"given":"Dipal M.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee F.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Gharibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"5","key":"1007_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1053\/j.ajkd.2020.03.022","volume":"76","author":"AM Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez AM et al (2020) Patient and caregiver priorities for outcomes in CKD: a multinational nominal group technique study. Am J Kidney Dis 76(5):679\u2013689","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1007_CR2","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2215\/CJN.01840220","volume":"15","author":"JM Evans","year":"2020","unstructured":"Evans JM et al (2020) Implementing a Patient-reported outcome measure for hemodialysis patients in Routine clinical Care: perspectives of patients and providers on ESAS-r: renal. Clin J Am Soc Nephrol 15(9):1299\u20131309","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1007_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1053\/j.ajkd.2019.02.011","volume":"74","author":"OL Aiyegbusi","year":"2019","unstructured":"Aiyegbusi OL et al (2019) Patient and clinician Perspectives on Electronic Patient-reported outcome measures in the management of advanced CKD: a qualitative study. Am J Kidney Dis 74(2):167\u2013178","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1007_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/msc.1379","volume":"17","author":"DN Bernstein","year":"2019","unstructured":"Bernstein DN et al (2019) Patient-reported outcomes use during orthopaedic surgery clinic visits improves the patient experience. Musculoskeletal Care 17(1):120\u2013125","journal-title":"Musculoskeletal Care"},{"issue":"7","key":"1007_CR5","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/rheumatology\/kez506","volume":"59","author":"SJ Bartlett","year":"2020","unstructured":"Bartlett SJ et al (2020) Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results. Rheumatol (Oxford) 59(7):1662\u20131670","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"1007_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/kidneydial2010012","volume":"2","author":"CJ Lightfoot","year":"2022","unstructured":"Lightfoot CJ et al (2022) Patient activation: the cornerstone of effective self-management in chronic kidney disease? Kidney Dial 2(1):91\u2013105","journal-title":"Kidney Dial"},{"key":"1007_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jclinepi.2017.04.017","volume":"89","author":"VK Noonan","year":"2017","unstructured":"Noonan VK et al (2017) Montreal Accord on Patient-reported outcomes (PROs) use series - Paper, 3: patient-reported outcomes can facilitate shared decision-making and guide self-management. J Clin Epidemiol 89:125\u2013135","journal-title":"J Clin Epidemiol"},{"key":"1007_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2017.04.018","volume":"89","author":"H Mamiya","year":"2017","unstructured":"Mamiya H et al (2017) Montreal Accord on Patient-reported outcomes (PROs) use series - Paper, 5: patient-reported outcomes can be linked to epidemiologic measures to monitor populations and inform public health decisions. J Clin Epidemiol 89:142\u2013147","journal-title":"J Clin Epidemiol"},{"key":"1007_CR9","first-page":"e2300182","volume":"7","author":"DA Patt","year":"2023","unstructured":"Patt DA et al (2023) Impact of remote symptom Monitoring with Electronic Patient-reported outcomes on Hospitalization, Survival, and cost in community oncology Practice: the Texas two-step study. JCO Clin Cancer Inf 7:e2300182","journal-title":"JCO Clin Cancer Inf"},{"issue":"10","key":"1007_CR10","first-page":"4933","volume":"28","author":"D Howell","year":"2020","unstructured":"Howell D et al (2020) Integration of patient-reported outcomes (PROs) for personalized symptom management in \u201creal-world\u201d oncology practices: a population-based cohort comparison study of impact on healthcare utilization. Support Care Cancer 28(10):4933\u20134942","journal-title":"Support Care Cancer"},{"issue":"6","key":"1007_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E et al (2016) Symptom Monitoring with Patient-reported outcomes during Routine Cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557\u2013565","journal-title":"J Clin Oncol"},{"key":"1007_CR12","doi-asserted-by":"crossref","unstructured":"Hughes A et al (2024) Core Patient-reported outcomes for trials in nephrology. Semin Nephrol 44(3)","DOI":"10.1016\/j.semnephrol.2024.151549"},{"key":"1007_CR13","unstructured":"Matus Gonzalez A et al A core outcome set for trials in CKD: report of the standardized outcomes in nephrology-chronic kidney disease (SONG-CKD) stakeholder workshops. Am J Kidney Dis"},{"issue":"1","key":"1007_CR14","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","volume":"9","author":"ME Stauffer","year":"2014","unstructured":"Stauffer ME, Fan T (2014) Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE 9(1):e84943","journal-title":"PLoS One"},{"key":"1007_CR15","unstructured":"U.S. Renal Data System 2024 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD"},{"key":"1007_CR16","doi-asserted-by":"crossref","unstructured":"Babitt J L, Berns J, Bozkurt B, Rs C, Cuevas Y, Effa EE, Mf E, Fishbane S, Ginzburg YZ, Haase V, Hedayati S, Kim S, Moura-Neto JA, Nagler EV, Rossignol P, Sahay M, Tanaka T, Wang AY, Wheeler D, Robinson KA, Wilson LM, Wilson RF, Earley A, Akl E, Tonelli M KDIGO 2026 clinical Practice guideline for the management of anemia in chronic kidney disease: Executive summary. Kidney Int. [In Press]","DOI":"10.1016\/j.kint.2025.06.005"},{"issue":"8","key":"1007_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","volume":"309","author":"M Calvert","year":"2013","unstructured":"Calvert M et al (2013) Reporting of Patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814\u2013822","journal-title":"JAMA"},{"key":"1007_CR18","doi-asserted-by":"publisher","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for scoping seviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):67\u2013473. https:\/\/doi.org\/10.7326\/M18-0850 Epub 2018 Sep 4. PMID: 30178033.","DOI":"10.7326\/M18-0850"},{"key":"1007_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J et al (2016) PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 75:40\u201346","journal-title":"J Clin Epidemiol"},{"issue":"22","key":"1007_CR20","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","volume":"333","author":"S Hopewell","year":"2025","unstructured":"Hopewell S et al (2025) CONSORT, 2025 statement: updated guideline for reporting randomized trials. JAMA 333(22):1998\u20132005","journal-title":"JAMA"},{"issue":"6","key":"1007_CR21","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","volume":"68","author":"DB Van Wyck","year":"2005","unstructured":"Van Wyck DB et al (2005) A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68(6):2846\u20132856","journal-title":"Kidney Int"},{"issue":"5","key":"1007_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000096174","volume":"26","author":"R Agarwal","year":"2006","unstructured":"Agarwal R et al (2006) A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26(5):445\u2013454","journal-title":"Am J Nephrol"},{"issue":"17","key":"1007_CR23","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","volume":"50","author":"JE Toblli","year":"2007","unstructured":"Toblli JE et al (2007) Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50(17):1657\u20131665","journal-title":"J Am Coll Cardiol"},{"key":"1007_CR24","first-page":"OC18","volume":"11","author":"J Toblli","year":"2017","unstructured":"Toblli J, Gennaro F (2017) Long-term effect of intravenous iron on overall survival and hospitalization in patients with heart failure with reduced ejection fraction, iron deficiency and mild renal impairment: an open-label 5-year follow up observation. J Clin Diagnostic Res 11:OC18\u2013OC24","journal-title":"J Clin Diagnostic Res"},{"issue":"11","key":"1007_CR25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/eurjhf\/hfp140","volume":"11","author":"SD Anker","year":"2009","unstructured":"Anker SD et al (2009) Rationale and design of ferinject assessment in patients with iron deficiency and chronic heart failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 11(11):1084\u20131091","journal-title":"Eur J Heart Fail"},{"issue":"25","key":"1007_CR26","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436\u20132448","journal-title":"N Engl J Med"},{"issue":"1","key":"1007_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/eurheartj\/ehr504","volume":"34","author":"J Comin-Colet","year":"2013","unstructured":"Comin-Colet J et al (2013) The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 34(1):30\u201338","journal-title":"Eur Heart J"},{"issue":"3","key":"1007_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ejhf.229","volume":"17","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P et al (2015) The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 17(3):329\u2013339","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"1007_CR29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/ndt\/gft424","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC et al (2014) The FIND-CKD study-a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transpl 29(4):843\u2013850","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"1007_CR30","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC et al (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transpl 29(11):2075\u20132084","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"1007_CR31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ki.2015.163","volume":"88","author":"R Agarwal","year":"2015","unstructured":"Agarwal R, Kusek JW, Pappas MK (2015) A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 88(4):905\u2013914","journal-title":"Kidney Int"},{"issue":"4","key":"1007_CR32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ndt\/gfv293","volume":"31","author":"PA Kalra","year":"2016","unstructured":"Kalra PA et al (2016) A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transpl 31(4):646\u2013655","journal-title":"Nephrol Dial Transpl"},{"key":"1007_CR33","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.12659\/MSM.900520","volume":"23","author":"Y Deng","year":"2017","unstructured":"Deng Y, Wu J, Jia Q (2017) Efficacy of intravenous iron sucrose in hemodialysis patients with Restless Legs Syndrome (RLS): a randomized, placebo-controlled study. Med Sci Monit 23:1254\u20131260","journal-title":"Med Sci Monit"},{"issue":"5","key":"1007_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC et al (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447\u2013458","journal-title":"N Engl J Med"},{"issue":"6","key":"1007_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1159\/000507872","volume":"51","author":"S Bhandari","year":"2020","unstructured":"Bhandari S et al (2020) Protocol and baseline data of a multicentre prospective double-blinded randomized study of intravenous iron on functional status in patients with chronic kidney disease. Am J Nephrol 51(6):493\u2013500","journal-title":"Am J Nephrol"},{"issue":"1","key":"1007_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12882-021-02308-y","volume":"22","author":"S Bhandari","year":"2021","unstructured":"Bhandari S et al (2021) A multicentre prospective double blinded randomised controlled trial of intravenous iron (Ferric Derisomaltose (FDI)) in iron deficient but not anaemic patients with chronic kidney disease on functional status. BMC Nephrol 22(1):115","journal-title":"BMC Nephrol"},{"issue":"31","key":"1007_CR37","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","volume":"42","author":"EA Jankowska","year":"2021","unstructured":"Jankowska EA et al (2021) The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J 42(31):3011\u20133020","journal-title":"Eur Heart J"},{"issue":"9","key":"1007_CR38","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2215\/CJN.0000000000000223","volume":"18","author":"IC Macdougall","year":"2023","unstructured":"Macdougall IC et al (2023) Ferric Carboxymaltose in iron-deficient patients with hospitalized heart failure and reduced kidney function. Clin J Am Soc Nephrol 18(9):1124\u20131134","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1007_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12882-022-02896-3","volume":"23","author":"SA Greenwood","year":"2022","unstructured":"Greenwood SA et al (2022) The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial. BMC Nephrol, 23(1):268","journal-title":"BMC Nephrol,"},{"issue":"8","key":"1007_CR40","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.ekir.2023.05.002","volume":"8","author":"SA Greenwood","year":"2023","unstructured":"Greenwood SA et al (2023) A randomized trial of intravenous iron supplementation and exercise on exercise capacity in iron-deficient nonanemic patients with CKD. Kidney Int Rep 8(8):1496\u20131505","journal-title":"Kidney Int Rep"},{"key":"1007_CR41","doi-asserted-by":"crossref","unstructured":"Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis (1990) Can Erythropoietin Study Group. BMJ 300(6724):573\u2013578","DOI":"10.1136\/bmj.300.6724.573"},{"issue":"2 Suppl 1","key":"1007_CR42","first-page":"11","volume":"10","author":"A Laupacis","year":"1990","unstructured":"Laupacis A (1990) Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian erythropoietin study group. Semin Nephrol 10(2 Suppl 1):11\u201319","journal-title":"Semin Nephrol"},{"issue":"3","key":"1007_CR43","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1046\/j.1523-1755.2000.00289.x","volume":"58","author":"RN Foley","year":"2000","unstructured":"Foley RN et al (2000) Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58(3):1325\u20131335","journal-title":"Kidney Int"},{"issue":"2","key":"1007_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ndt\/18.2.353","volume":"18","author":"H Furuland","year":"2003","unstructured":"Furuland H et al (2003) A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transpl 18(2):353\u2013361","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"1007_CR45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/01.ASN.0000102471.89084.8B","volume":"15","author":"SD Roger","year":"2004","unstructured":"Roger SD et al (2004) Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15(1):148\u2013156","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"1007_CR46","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2004121039","volume":"16","author":"PS Parfrey","year":"2005","unstructured":"Parfrey PS et al (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16(7):2180\u20132189","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1007_CR47","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2215\/CJN.04950908","volume":"4","author":"RN Foley","year":"2009","unstructured":"Foley RN, Curtis BM, Parfrey PS (2009) Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol 4(4):726\u2013733","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1007_CR48","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1053\/j.ajkd.2006.02.170","volume":"47","author":"J Rossert","year":"2006","unstructured":"Rossert J et al (2006) Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 47(5):738\u2013750","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"1007_CR49","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Drueke","year":"2006","unstructured":"Drueke TB et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355(20):2071\u20132084","journal-title":"N Engl J Med"},{"issue":"20","key":"1007_CR50","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK et al (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355(20):2085\u20132098","journal-title":"N Engl J Med"},{"issue":"2","key":"1007_CR51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.ajkd.2006.11.032","volume":"49","author":"E Ritz","year":"2007","unstructured":"Ritz E et al (2007) Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the anemia correction in diabetes (ACORD) study. Am J Kidney Dis 49(2):194\u2013207","journal-title":"Am J Kidney Dis"},{"issue":"21","key":"1007_CR52","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019\u20132032","journal-title":"N Engl J Med"},{"issue":"4","key":"1007_CR53","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2215\/CJN.06450710","volume":"6","author":"EF Lewis","year":"2011","unstructured":"Lewis EF et al (2011) Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol 6(4):845\u2013855","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1007_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1681\/ASN.2011060546","volume":"23","author":"G Choukroun","year":"2012","unstructured":"Choukroun G et al (2012) Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 23(2):360\u2013368","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1007_CR55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1744-9987.2011.00931.x","volume":"15","author":"T Akizawa","year":"2011","unstructured":"Akizawa T et al (2011) Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Ther Apher Dial 15(5):431\u2013440","journal-title":"Ther Apher Dial"},{"issue":"2","key":"1007_CR56","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11255-013-0512-1","volume":"46","author":"SD Roger","year":"2014","unstructured":"Roger SD et al (2014) A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp(R) (darbepoetin alfa) in older people: STIMULATE. Int Urol Nephrol 46(2):469\u2013475","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"1007_CR57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3346\/jkms.2014.29.1.76","volume":"29","author":"J Oh","year":"2014","unstructured":"Oh J et al (2014) Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis. J Korean Med Sci 29(1):76\u201383","journal-title":"J Korean Med Sci"},{"issue":"9","key":"1007_CR58","first-page":"899","volume":"97","author":"B Satirapoj","year":"2014","unstructured":"Satirapoj B, Supasyndh O, Choovichian P (2014) A comparative study of efficacy and safety of the lyophilized powder alpha-erythropoietin and the liquid form alpha-erythropoietin for hemoglobin maintenance in patients with hemodialysis treatment. J Med Assoc Thai 97(9):899\u2013906","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"1007_CR59","doi-asserted-by":"publisher","first-page":"e0172735","DOI":"10.1371\/journal.pone.0172735","volume":"12","author":"V Saglimbene","year":"2017","unstructured":"Saglimbene V et al (2017) Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: a randomized clinical trial. PLoS ONE 12(3):e0172735","journal-title":"PLoS One"},{"key":"1007_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2147\/IJNRD.S143731","volume":"10","author":"B Satirapoj","year":"2017","unstructured":"Satirapoj B, Dispan R, Supasyndh O (2017) Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients. Int J Nephrol Renovasc Dis 10:275\u2013283","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"1","key":"1007_CR61","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00467-017-3758-5","volume":"33","author":"BA Warady","year":"2018","unstructured":"Warady BA et al (2018) De Novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. Pediatr Nephrol 33(1):125\u2013137","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1007_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.6002\/ect.2018.0283","volume":"18","author":"T Pile","year":"2020","unstructured":"Pile T et al (2020) Treating posttransplant anemia with erythropoietin improves quality of life but does not affect progression of chronic kidney disease. Exp Clin Transpl 18(1):27\u201333","journal-title":"Exp Clin Transpl"},{"key":"1007_CR63","doi-asserted-by":"crossref","unstructured":"Coyne DW et al (2021) Roxadustat for CKD-related anemia in non-dialysis Patients. Kidney Int Rep 6(3):624\u2013635","DOI":"10.1016\/j.ekir.2020.11.034"},{"issue":"3","key":"1007_CR64","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","volume":"32","author":"S Fishbane","year":"2021","unstructured":"Fishbane S et al (2021) Roxadustat for Treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol 32(3):737\u2013755","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1007_CR65","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","volume":"38","author":"B Csiky","year":"2021","unstructured":"Csiky B et al (2021) Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, Open-label, active-controlled study (PYRENEES). Adv Ther 38(10):5361\u20135380","journal-title":"Adv Ther"},{"key":"1007_CR66","doi-asserted-by":"crossref","unstructured":"Altman D, Simera I (2014) Using reporting guidelines effectively to ensure good reporting of health Research 32\u201340","DOI":"10.1002\/9781118715598.ch4"},{"issue":"6","key":"1007_CR67","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/s41591-025-03635-5","volume":"31","author":"S Hopewell","year":"2025","unstructured":"Hopewell S et al (2025) CONSORT, 2025 statement: updated guideline for reporting randomized trials. Nat Med 31(6):1776\u20131783","journal-title":"Nat Med"},{"key":"1007_CR68","unstructured":"Enhancingthe quality and transparency of health research (EQUATOR) network. [cited 2025 June 30]. Available from https:\/\/www.equator-network.org\/"},{"issue":"1","key":"1007_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.ajkd.2006.10.012","volume":"49","author":"K Uhlig","year":"2007","unstructured":"Uhlig K, Menon V, Schmid CH (2007) Recommendations for reporting of clinical Research studies. Am J Kidney Dis 49(1):3\u20137","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"1007_CR70","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/ki.2012.335","volume":"82","author":"S Fishbane","year":"2012","unstructured":"Fishbane S et al (2012) Quality of reporting of randomization methodology in nephrology trials. Kidney Int 82(11):1144\u20131146","journal-title":"Kidney Int"},{"issue":"8","key":"1007_CR71","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s40620-024-01977-w","volume":"37","author":"P Crotty","year":"2024","unstructured":"Crotty P et al (2024) A cross-sectional analysis of reporting guideline and clinical trial registration policies in nephrology journals. J Nephrol 37(8):2171\u20132180","journal-title":"J Nephrol"},{"issue":"12","key":"1007_CR72","doi-asserted-by":"publisher","first-page":"e058197","DOI":"10.1136\/bmjopen-2021-058197","volume":"12","author":"P van der Vet","year":"2022","unstructured":"van der Vet P et al (2022) Quality and reporting of patient-reported outcomes in elderly patients with hip fracture: a systematic review. BMJ Open 12(12):e058197","journal-title":"BMJ Open"},{"key":"1007_CR73","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bjps.2024.09.022","volume":"99","author":"T Milazzo","year":"2024","unstructured":"Milazzo T et al (2024) Reporting of patient-reported outcomes amongst randomized clinical trials in plastic surgery: a systematic review using CONSORT-PRO. J Plast Reconstr Aesthet Surg 99:110\u2013121","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"9","key":"1007_CR74","doi-asserted-by":"publisher","first-page":"e2231930","DOI":"10.1001\/jamanetworkopen.2022.31930","volume":"5","author":"A Fabian","year":"2022","unstructured":"Fabian A et al (2022) Use and reporting of Patient-reported outcomes in trials of palliative radiotherapy: a systematic review. JAMA Netw Open 5(9):e2231930","journal-title":"JAMA Netw Open"},{"key":"1007_CR75","first-page":"100962","volume":"83","author":"T Moore","year":"2023","unstructured":"Moore T et al (2023) Underreporting of patient-reported outcomes in cystic fibrosis randomized controlled trials using CONSORT-PRO and RoB 2.0. Respir Med Res 83:100962","journal-title":"Respir Med Res"},{"key":"1007_CR76","volume-title":"The COMET (core outcome measures in Effectiveness trials) initiative","author":"PR Williamson","year":"1745","unstructured":"Williamson PR et al (1745-6215) The COMET (Core Outcome Measures in Effectiveness Trials) initiative. Electronic"},{"issue":"12","key":"1007_CR77","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/ndt\/gfx288","volume":"32","author":"A Tong","year":"2017","unstructured":"Tong A et al (2017) Composing a new song for trials: the standardized outcomes in nephrology (SONG) initiative. Nephrol Dial Transpl 32(12):1963\u20131966","journal-title":"Nephrol Dial Transpl"},{"key":"1007_CR78","first-page":"Patient","volume-title":"The benefits and challenges of using multiple sources of information about clinical trials","author":"K Dickersin","year":"2018","unstructured":"Dickersin K, Mayo-Wilson E, Li T (2018) PCORI final research reports. In: The benefits and challenges of using multiple sources of information about clinical trials. Outcomes Research Institute (PCORI), pp Patient-CenteredCopyright \u00a9 2018 Johns Hopkins University. All Rights Reserved.:Washington (DC)"},{"issue":"7","key":"1007_CR79","doi-asserted-by":"publisher","first-page":"e099592","DOI":"10.1136\/bmjopen-2025-099592","volume":"15","author":"A Hughes","year":"2025","unstructured":"Hughes A et al (2025) Patient-reported outcome measures for fatigue in patients with chronic kidney disease: a systematic review. BMJ Open 15(7):e099592","journal-title":"BMJ Open"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01007-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:39:03Z","timestamp":1781635143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01007-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01007-2","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}